This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Screening (alpha feto protein, maternal)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Measurement of maternal AFP levels is a useful tool in the prenatal diagnosis of many fetal disorders, including Down's syndrome, spina bifida, anencephaly and others.

Broadly the findings in AFP levels can be grouped into:

  • High AFP
  • Low AFP

The maternal blood is taken at 16 weeks gestation - an accurate estimation of gestational age is needed in order to allow the proper significance of a result to be assessed. The outcome of the test is to prompt further investigations if positive - i.e. it is not diagnostic.

  • in the UK, maternal AFP is assessed in the context of other markers e .g. the quadruple test (hCG, AFP, uE3, inhibin A) to give a more accurate predictor of risk. However as many Trusts in England move to the offer of combined screening for Down's syndrome, AFP will no longer be measured and the screening test of choice for spina bifida and anencephaly will be the mid pregnancy ultrasound scan

 


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.